Hologic has now acquired Biotheranostics, developer of two highly differentiated molecular diagnostic tests for breast and metastatic cancers – Breast Cancer Index™ (BCI) and CancerTYPE ID® (CTID).
Breast Cancer Index predicts which early-stage hormone receptor positive (HR+) breast cancer patients are likely to benefit from extended endocrine therapy and is included in clinical practice guidelines from prominent organizations including the National Comprehensive Cancer Network® (NCCN®) and the American Society for Clinical Oncology (ASCO). Terminating endocrine therapy in those patients unlikely to benefit may save healthcare dollars and reduce patient exposure to challenging side effects of therapy.
Cancer TYPE ID provides a molecular diagnosis for patients with uncertain or unknown cancers. In advanced cancer that has metastasized, it can be difficult to determine the tumor type and subtype, information that is needed to optimize treatment selection.
“We are very pleased to complete the acquisition of Biotheranostics and look forward to working with our new colleagues to grow in the large, rapidly expanding oncology space. We are even more excited about the acquisition because the National Comprehensive Cancer Network recently revised its clinical practice guidelines to include Breast Cancer Index as the only gene expression assay to predict benefit from extended endocrine therapy for patients with early-stage hormone-receptor positive breast cancer.” Kevin Thornal - President of Hologic’s Diagnostic Solutions Division
“We are thrilled that the Biotheranostics team will become part of Hologic’s diagnostic business. Hologic’s leadership in women’s health and molecular automation will accelerate access for both of our novel, proprietary tests, translating into better clinical outcomes for cancer patients. For Breast Cancer Index (BCI), our long-held belief is that all women who are being treated with endocrine therapy for their breast cancer deserve to know what is right for them. Being part of Hologic only helps bring that hope closer to reality. In addition, patients facing the challenges of metastatic cancer will have broader access to our CancerTYPE ID offering that can aid in the diagnosis of the tumor type and subtypes representing 95% of all solid tumors.” Don Hardison - Biotheranostics’ President and Chief Executive Officer
Both of Biotheranostics’ tests are PCR (polymerase chain reaction)-based gene expression tests that have been extensively validated in large studies in areas of oncology with critical unmet needs.